These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 26795875)

  • 1. Acetylcholinesterase inhibitors and gait: a steadying hand?
    Moreau C; Devos D; Defebvre L
    Lancet Neurol; 2016 Mar; 15(3):232-3. PubMed ID: 26795875
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Henderson EJ; Lord SR; Brodie MA; Gaunt DM; Lawrence AD; Close JC; Whone AL; Ben-Shlomo Y
    Lancet Neurol; 2016 Mar; 15(3):249-58. PubMed ID: 26795874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rivastigmine and Parkinson's disease without dementia : Impact on gait stability and frequency of falling].
    Amadori K
    Z Gerontol Geriatr; 2016 Oct; 49(7):662-663. PubMed ID: 27599816
    [No Abstract]   [Full Text] [Related]  

  • 4. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.
    Mamikonyan E; Xie SX; Melvin E; Weintraub D
    Mov Disord; 2015 Jun; 30(7):912-8. PubMed ID: 25914281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
    Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
    Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two cholinesterase inhibitors trigger dissimilar effects on behavior and body weight in C57BL/6 mice: The case of chlorpyrifos and rivastigmine.
    Basaure P; Peris-Sampedro F; Cabré M; Reverte I; Colomina MT
    Behav Brain Res; 2017 Feb; 318():1-11. PubMed ID: 27732893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquisition and reinstatement of ethanol-induced conditioned place preference in rats: Effects of the cholinesterase inhibitors donepezil and rivastigmine.
    Gawel K; Labuz K; Gibula-Bruzda E; Jenda M; Marszalek-Grabska M; Silberring J; Kotlinska JH
    J Psychopharmacol; 2016 Jul; 30(7):676-87. PubMed ID: 27097732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.
    Foley PB
    Neurology; 2011 Dec; 77(23):e140; author reply e140. PubMed ID: 22146929
    [No Abstract]   [Full Text] [Related]  

  • 9. Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors.
    Wang L; Wang Y; Tian Y; Shang J; Sun X; Chen H; Wang H; Tan W
    Bioorg Med Chem; 2017 Jan; 25(1):360-371. PubMed ID: 27856236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacologic treatment of gait ignition failure.
    Rascol O; Fabre N; Brefel-Courbon C; Montastruc JL
    Adv Neurol; 2001; 87():255-64. PubMed ID: 11347230
    [No Abstract]   [Full Text] [Related]  

  • 11. Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease.
    Cummings JL
    J Neurol Neurosurg Psychiatry; 2005 Jul; 76(7):903-4. PubMed ID: 15965192
    [No Abstract]   [Full Text] [Related]  

  • 12. [Design, synthesis and evaluation of N-acyl-4-phenylthiazole-2-amines as acetylcholinesterase inhibitors].
    Ma ZY; Yang Q; Zhang YG; Li JJ; Yang GL
    Yao Xue Xue Bao; 2014 Jun; 49(6):813-8. PubMed ID: 25212025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of 24-h continuous rotigotine treatment on stationary and non-stationary locomotion in de novo patients with Parkinson disease in an open-label uncontrolled study.
    Serrao M; Ranavolo A; Conte C; Davassi C; Mari S; Fasano A; Chini G; Coppola G; Draicchio F; Pierelli F
    J Neurol; 2015 Nov; 262(11):2539-47. PubMed ID: 26303834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinesterase inhibitors, donepezil and rivastigmine, attenuate spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats.
    Gawel K; Labuz K; Gibula-Bruzda E; Jenda M; Marszalek-Grabska M; Filarowska J; Silberring J; Kotlinska JH
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1059-71. PubMed ID: 27376896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns and predictors of freezing of gait improvement following rasagiline therapy: A pilot study.
    Rahimi F; Roberts AC; Jog M
    Clin Neurol Neurosurg; 2016 Nov; 150():117-124. PubMed ID: 27618783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.
    Eskander MF; Nagykery NG; Leung EY; Khelghati B; Geula C
    Brain Res; 2005 Oct; 1060(1-2):144-52. PubMed ID: 16212945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into (S)-rivastigmine inhibition of butyrylcholinesterase (BuChE): Molecular docking and saturation transfer difference NMR (STD-NMR).
    Bacalhau P; San Juan AA; Goth A; Caldeira AT; Martins R; Burke AJ
    Bioorg Chem; 2016 Aug; 67():105-9. PubMed ID: 27317888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine for freezing of gait in Parkinson disease.
    Jankovic J
    J Neurol Sci; 2009 Sep; 284(1-2):177-8. PubMed ID: 19361809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
    Xiao G; Li Y; Qiang X; Xu R; Zheng Y; Cao Z; Luo L; Yang X; Sang Z; Su F; Deng Y
    Bioorg Med Chem; 2017 Feb; 25(3):1030-1041. PubMed ID: 28011206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivastigmine improves isolation rearing-induced prepulse inhibition deficits via muscarinic acetylcholine receptors in mice.
    Higashino K; Ago Y; Umeki T; Hasebe S; Onaka Y; Hashimoto H; Takuma K; Matsuda T
    Psychopharmacology (Berl); 2016 Feb; 233(3):521-8. PubMed ID: 26518025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.